Control of cardiac valve related hemolytic anemia by sulphinpyrazone.
Sulphinpyrazone has a beneficial effect in a patient with hemolytic anemia related to cardiac valve prostheses. It may also have a clinically significant role in the control of symptoms and may delay the need for surgery.